bipolar disorder

FDA approves first pill that can be tracked when ingestedFDA approved the first drug in the United States that has a digital ingestion tracking system, which records when the medication was taken.
Depression: How to treat, avoid misdiagnosisDepression is one of the most common diagnosed disorders but providers still have trouble diagnosing and treating these patients.
Big savings expected with new generic antipsychoticFDA tentatively approved the abbreviated new drug application (ANDA) for generic quetiapine fumarate extended-release tablets (brand Seroquel XR, AstraZeneca) to treat schizophrenia and manic/mixed episodes associated with bipolar disorder.
Brand-name patent losses raise pharma cost concernsA number of traditional brand-name pharmaceuticals have lost, or will lose, patent protection this year. What does this mean over the longer-term for controlling costs?
New treatment approved for bipolar disorder, schizophreniaFDA has approved cariprazine (Vraylar) capsules, an atypical antipsychotic, indicated for the treatment of adults with schizophrenia as well as bipolar I disorder, based on controlled trials of more than 2,700 individuals.
Bipolar disorder in children: Assessment and diagnosisBipolar disorder is a serious mental health disorder that is often first diagnosed during young adulthood or adolescence. Symptoms of the illness, however, also can appear in early childhood.
FDA approves first generic AbilifyThe FDA approved the first generic versions of Abilify (aripiprazole), an antipsychotic drug approved to treat schizophrenia and bipolar disorder, on April 28.
Children’s use of antipsychotics may increase risk of diabetesInitiating antipsychotics may elevate a child’s risk not only for significant weight gain, but also for type 2 diabetes by nearly 50%, according to a study in JAMA Pediatrics. Moreover, among children who are also receiving antidepressants, the risk may double.
Teenager battles daytime sleep attacksA 17-year-old-male presented to a specialty clinic for follow-up of attention-deficit/hyperactivity disorder (ADHD), migraine headaches, adjustment disorder with mixed disturbance of emotion and conduct, and mood disorder. At this visit, he reported excessive daytime sleepiness that was interfering with academic tasks and “life.”
First atypical antipsychotic approved for pediatric patients with bipolar I disorder in 5 yearsFDA has approved asenapine (Saphris, Actavis) for treatment of manic or mixed episodes of bipolar I disorder in pediatric patients, ages 10 to 17 years old.